PURPOSE: The aim of this study was to evaluate the pharmacokinetics of paclitaxel-loaded lipid nanocapsules (LNC) in rats to assess the intrinsic effect of the dosage form on the improvement of paclitaxel oral exposure. METHODS: Paclitaxel-loaded LNC were prepared and characterized in terms of size distribution, drug payload, and the kinetics of paclitaxel crystallization. Taxol, Taxol with verapamil, or paclitaxel-loaded LNC were administered orally to rats. The plasma concentration of paclitaxel was determined using liquid chromatography mass spectrometry. RESULTS: The average size of LNC was 60.9 +/- 1.5 nm. The drug payload of paclitaxel was 1.91 +/- 0.01 mg/g of aqueous dispersion. The encapsulation efficiency was 99.9 +/- 1.0%, and 1.7 +/- 0.1% of paclitaxel was crystallized after 24 h. The oral bioavailability of Taxol alone was 6.5%. After oral administration of paclitaxel-loaded LNC or paclitaxel associated with verapamil, the area under the plasma concentration-time curve was significantly increased (about 3-fold) in comparison to the control group (p < 0.05). CONCLUSIONS: The results indicated that LNC provided a promising new formulation to enhance the oral bioavailability of paclitaxel while avoiding the use of pharmacologically active P-gp inhibitors, such as verapamil.
PURPOSE: The aim of this study was to evaluate the pharmacokinetics of paclitaxel-loaded lipid nanocapsules (LNC) in rats to assess the intrinsic effect of the dosage form on the improvement of paclitaxel oral exposure. METHODS:Paclitaxel-loaded LNC were prepared and characterized in terms of size distribution, drug payload, and the kinetics of paclitaxel crystallization. Taxol, Taxol with verapamil, or paclitaxel-loaded LNC were administered orally to rats. The plasma concentration of paclitaxel was determined using liquid chromatography mass spectrometry. RESULTS: The average size of LNC was 60.9 +/- 1.5 nm. The drug payload of paclitaxel was 1.91 +/- 0.01 mg/g of aqueous dispersion. The encapsulation efficiency was 99.9 +/- 1.0%, and 1.7 +/- 0.1% of paclitaxel was crystallized after 24 h. The oral bioavailability of Taxol alone was 6.5%. After oral administration of paclitaxel-loaded LNC or paclitaxel associated with verapamil, the area under the plasma concentration-time curve was significantly increased (about 3-fold) in comparison to the control group (p < 0.05). CONCLUSIONS: The results indicated that LNC provided a promising new formulation to enhance the oral bioavailability of paclitaxel while avoiding the use of pharmacologically active P-gp inhibitors, such as verapamil.
Authors: K H Diehl; R Hull; D Morton; R Pfister; Y Rabemampianina; D Smith; J M Vidal; C van de Vorstenbosch Journal: J Appl Toxicol Date: 2001 Jan-Feb Impact factor: 3.446
Authors: J M Meerum Terwogt; M M Malingré; J H Beijnen; W W ten Bokkel Huinink; H Rosing; F J Koopman; O van Tellingen; M Swart; J H Schellens Journal: Clin Cancer Res Date: 1999-11 Impact factor: 12.531
Authors: M M Malingré; J H Beijnen; H Rosing; F J Koopman; O van Tellingen; K Duchin; W W Ten Bokkel Huinink; M Swart; J Lieverst; J H Schellens Journal: Cancer Chemother Pharmacol Date: 2001-04 Impact factor: 3.333
Authors: K S Lown; R R Mayo; A B Leichtman; H L Hsiao; D K Turgeon; P Schmiedlin-Ren; M B Brown; W Guo; S J Rossi; L Z Benet; P B Watkins Journal: Clin Pharmacol Ther Date: 1997-09 Impact factor: 6.875
Authors: J van Asperen; O van Tellingen; A Sparreboom; A H Schinkel; P Borst; W J Nooijen; J H Beijnen Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner Journal: Nat Rev Drug Discov Date: 2010-08 Impact factor: 84.694
Authors: Bilal S Abuasal; Courtney Lucas; Breanne Peyton; Alaadin Alayoubi; Sami Nazzal; Paul W Sylvester; Amal Kaddoumi Journal: Lipids Date: 2012-01-24 Impact factor: 1.880
Authors: Sang Cheon Lee; Kang Moo Huh; Jaehwi Lee; Yong Woo Cho; Raymond E Galinsky; Kinam Park Journal: Biomacromolecules Date: 2007-01 Impact factor: 6.988
Authors: G V Ullio Gamboa; S D Palma; A Lifschitz; M Ballent; C Lanusse; C Passirani; J P Benoit; D A Allemandi Journal: Parasitol Res Date: 2016-02-06 Impact factor: 2.289